| scholarly article | Q13442814 |
| P50 | author | Marleen Boelaert | Q28817180 |
| Thomas P C Dorlo | Q80834537 | ||
| P2093 | author name string | Bart Ostyn | |
| Epco Hasker | |||
| Jean-Claude Dujardin | |||
| Suman Rijal | |||
| Bruno Dujardin | |||
| Surendra Uranw | |||
| P2860 | cites work | Leishmaniasis worldwide and global estimates of its incidence | Q21134611 |
| Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic | Q28142100 | ||
| Adherence to Medication | Q28314923 | ||
| Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice | Q33707148 | ||
| Measuring adherence to behavioral and medical interventions | Q34052961 | ||
| Adherence to self-administered tuberculosis treatment in a high HIV-prevalence setting: a cross-sectional survey in Homa Bay, Kenya | Q34199723 | ||
| Oral miltefosine for Indian visceral leishmaniasis | Q34529393 | ||
| Medication adherence: WHO cares? | Q34627451 | ||
| Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh | Q35065586 | ||
| Optimal dosing of miltefosine in children and adults with visceral leishmaniasis | Q36086339 | ||
| A policy for leishmaniasis with respect to the prevention and control of drug resistance | Q38924387 | ||
| Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). | Q39444314 | ||
| Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. | Q46714428 | ||
| Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. | Q53891579 | ||
| P433 | issue | 2 | |
| P921 | main subject | Nepal | Q837 |
| miltefosine | Q411787 | ||
| visceral leishmaniasis | Q2046113 | ||
| P304 | page(s) | 179-187 | |
| P577 | publication date | 2012-11-30 | |
| P1433 | published in | Tropical Medicine and International Health | Q15765747 |
| P1476 | title | Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal | |
| P478 | volume | 18 |
| Q41705604 | Challenges in modeling complexity of neglected tropical diseases: a review of dynamics of visceral leishmaniasis in resource limited settings |
| Q33602811 | Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis |
| Q28306178 | Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure |
| Q21132005 | Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia |
| Q35345427 | From health advice to taboo: community perspectives on the treatment of sleeping sickness in the Democratic Republic of Congo, a qualitative study |
| Q60924667 | Leishmanicidal Activity of Withanolides from var. |
| Q36395995 | The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery |
| Q39547251 | Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model |
| Q54961274 | Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most. |
Search more.